BDTX

Black Diamond Therapeutics, Inc.

4.50 USD
-0.28 (-5.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Black Diamond Therapeutics, Inc. stock is up 13.07% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 March’s closed higher than February.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.